Organigram's Sanity-Driven Transformation: Record Revenue, Record EBITDA, and a Global Pivot
With Sanity Group consolidated, Organigram reports its best quarter ever and shifts to an international-first growth model.
OGI.TO · Earnings Call · 2026-08-11
A Transformative Quarter
Organigram Global's third quarter of fiscal 2026 was a watershed moment. The company delivered its largest revenue quarter in history—$105.8 million, up 49% year-over-year—and record adjusted EBITDA of $13.4 million, a 136% jump from the prior year. “Organigram delivered the largest revenue quarter in the company's history, improved adjusted gross margin both sequentially and year-over-year, and generated record adjusted EBITDA.” — Greg Guyatt, CFO · 2026-08-11 The numbers alone tell a story of scale and profitability, but the real narrative is one of structural transformation. The catalyst was the consolidation of Sanity Group, the German cannabis distributor Organigram acquired in April. For the first time, the quarterly results include nearly a full quarter of Sanity's contributions, and the impact is unmistakable. International revenue now represents roughly 35% of consolidated revenues, up from about 10% before the acquisition. “approximately 35% of our consolidated revenues was generated internationally this quarter, compared to roughly 10% prior to the acquisition.” — James Yamanaka, CEO · 2026-08-11 Sanity itself delivered EUR 24.5 million in revenue since consolidation on April 15, and EUR 25.5 million for the full fiscal quarter—in line with expectations set at the time of the deal. CEO James Yamanaka highlighted that "the integration of Sanity is progressing according to plan, and it's already meaningfully reshaping Organigram's financial profile." This is not a small incremental step; it is a pivot toward a diversified, international-first business model.Canadian Execution and the Road Ahead
While the international story dominates, Organigram also made notable progress on the domestic front. The company's overall Canadian market share stood at 11.1% at quarter end. More importantly, corrective actions in vapes and infused pre-rolls—categories that suffered execution issues in Q2—began to show results. Vape share increased 1.1 percentage points month-over-month in June, and infused pre-rolls returned to growth. “the corrective actions we've taken across our Canadian business are beginning to produce encouraging results, particularly in categories where we experienced temporary execution challenges earlier this year.” — James Yamanaka, CEO · 2026-08-11 The company also cut SKU count by 10% to streamline its portfolio and improve margins. Flower remains a standout: share reached 12.5%, up 2 points year-over-year, driven by record THC potency (30.4% at Moncton) and 25% higher harvest volumes. The Canadian business is being repositioned for efficiency, even as the company expands internationally. Margins are improving across the board. Adjusted gross margin came in at 37%, up 300 basis points year-over-year and 600 sequentially, helped by Sanity's contribution and better Canadian operations. SG&A as a percentage of revenue dropped to 31% from 34%, reflecting operating leverage. CFO Greg Guyatt noted that the company expects margins to continue improving, especially as the EU GMP certification for its Moncton facility comes through. That certification, still pending, would eliminate the need for a European processor and further boost international margins. However, Guyatt acknowledged that "we don't have any new news" on EU GMP, but the company remains confident in its eventual approval. Cash flow was a mixed story. Operating cash flow before working capital changes turned positive at $6.2 million, but heavy working capital investment—largely inventory for growing German demand—pushed free cash flow to a negative $3.9 million for the quarter. The company reiterated its expectation of positive free cash flow in Q4, which it believes will be a better indicator of the business's cash-generating capacity. For the full year, Organigram still guides to revenue above $350 million, with adjusted gross margin and adjusted EBITDA meaningfully exceeding fiscal 2025 levels. The international expansion is not just about scale; it's about diversification. Sanity is growing its footprint across Europe, with new partnerships in Switzerland, Poland, and the U.K. The German market remains strong, but management is mindful of regulatory changes. A recent German rule disallowing medical cannabis reimbursement is expected to have minimal impact, as only about 1% of Sanity's sales were government-insured. In the U.S., Organigram is "bullish" on rescheduling and federal legalization, but has paused business development until regulatory clarity emerges around the hemp-derived THC ban. Australia remains a key focus, with the company expanding its portfolio to drive physician adoption.Contrast with Prior Themes
This quarter's results mark a clear departure from the challenges of earlier fiscal 2026. In the Q1 call, management had to address the impact of flower supply issues on international volumes. CFO Greg Guyatt quantified the impact at that time:By contrast, this quarter the company is talking about record international revenue and how it is "delighting" with Sanity's performance. The strategic focus has shifted from fixing supply constraints to scaling a global platform. Management's insistence on operational discipline has been a recurring theme. In the prior quarter, CEO James Yamanaka said: “it's really about operational execution, making sure that we really have a focus on executing with precision, focusing on the cost base, improving the margins and make sure we deliver to the market.” — James Yamanaka, Chief Executive Officer · 2026-02-10 That focus is now delivering tangible results. The margin profile is improving, and the company's flower supply is being better allocated between Canadian and international markets.the impact of that was probably about $3.5 million on revenue of international.
This confidence in German margins is a notable positive, especially given the industry-wide concerns about price compression in that market. In summary, Organigram has executed a strategic pivot that is already paying off. The consolidation of Sanity Group has fundamentally changed the company's revenue mix, financial profile, and growth trajectory. With record revenue, record EBITDA, and improving margins, Organigram is no longer just a Canadian LP; it is becoming a global cannabis player. The path ahead is not without risks—EU GMP timing, U.S. regulatory uncertainty, and the need to manage working capital—but the evidence from this quarter suggests the company is confident and executing well. For investors, the key takeaway is that Organigram today is a different and more diversified business than it was at the start of the year, and the market is taking notice.As of right now, our margins are operating in line with what we expected as well along with revenue. To your point about the competitive environment in Germany, right now there's a ton of demand, and we haven't seen significant price compression over the last quarter.